3 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow rhC1INH: new trials by email Literature Review of rhC1INH trials Research Report on rhC1INH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor Recombinant human C1 inhibitor, Placebo - Hereditary Angioedema | Phase 2 | Completed | Pharming Technologies B.V. | 32 | 2014-12-01 | 2017-12-08 |
| Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients rhC1INH - Hereditary Angioedema | Phase 2 | Completed | Pharming Technologies B.V. | 57 | 2012-01-17 | 2024-03-29 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema i.v. recombinant human C1 inhibitor - Genetic Disorders | Phase 2 / Phase 3 | Completed | Pharming Technologies B.V. | 14 | 2004-04-01 | 2013-02-22 |
Angioedemas, Hereditary (2) · Angioedema (1) · Genetic Diseases, Inborn (1)
Pharming Technologies B.V. (3)
Czechia (2) · Italy (2) · North Macedonia (2) · Romania (2) · United States (2) · Canada (1) · Germany (1) · Hungary (1) · Israel (1) · Netherlands (1) · Poland (1) · Serbia (1) · Slovakia (1)
Anurag Relan, MD (1) · Jan Nuijens, MD, PhD (1)